Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

major thrombotic cardiovascular events

Sanofi reception

Sanofi gains accelerated review for rare disease drug

New pill for Fabry disease could be approved by the FDA before the end of the year

- PMLiVE

Merck’s breakthrough HCV drug aces trial

Grazoprevir/elbasvir showed efficacy in phase II and III trials

- PMLiVE

Merck files Keytruda for lung cancer

Filed to the FDA as a treatment option for NSCLC patients

- PMLiVE

AZ and Takeda drugs should carry heart failure warning

FDA panel claim diabetes drugs Onglyza and Nesina need label updates

- PMLiVE

Merck appoints head of combined life science business

Udit Batra is CEO and president of Merck Millipore

- PMLiVE

ReNeuron aiming to take second stem cell therapy into clinic

Will test its human retinal progenitor cell for genetic eye disease RP

- PMLiVE

FDA reviewer backs approval of TMC’s cangrelor

Claims it offers a small benefit over Sanofi’s Plavix

- PMLiVE

AZ’s Onglyza may increase mortality, says FDA

Kombiglyze also under scrutiny

- PMLiVE

Pfizer and Merck flesh out Xalkori alliance details

First stage of building a combined oncology sales organisation

- PMLiVE

US cancer drug prices ‘not rational’

New research from the medical journal JAMA adds to growing pressure over pricing

- PMLiVE

PD-1 cancer market overrated, says new report

The immuno-oncology market for new oncology drugs may be worth half of current expectations

- PMLiVE

Merck adds another immuno-oncology tie-up

Firm to test Keytruda with Syndax’s entinostat in melanoma and NSCLC

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links